Figure-a (Figure A)
Nemluvio Injection, Powder, Lyophilized, For Solution
Product Images NDC 0299-6220
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Nemluvio (NDC 0299-6220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Galderma Laboratories, L.p., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
30g-pen-carton (Pxxxxx X Nemo Ai Carton 30mg Fda 8.9)
Device-overview (Device Overview)
This is a detailed description of the NEMLUVIO Single-Dose Pre-Filled Dual-Chamber Pen. It includes instructions on the device's components such as the needle cover, gray rod, orange rod, gray cap, inspection window, lyophilized powder, water for dilution, activation knob, and usage illustrations (arrow indications for unlocked and locked icons). The text serves as a visual guide for users on how to ready and operate the pen before and after use.*
Figure-1 (Figure 1 July22)
This text provides information on the proportion of subjects with weekly average pain scores improvement of 24% in a clinical trial evaluating NEVLUVIO Q4W and placebo in two different arms of the study (Olympia 1 and Olympia 2). The improvement was reported to be 6% in one of the study arms.*
Figure-3 (Figure 3 July22)
This text provides information on the proportion of subjects achieving IGA success for different groups in two separate studies (Olympia 1 and Olympia 2) comparing NEMLUVIO Q4W versus placebo. The sample sizes for each group are also included.*
Figure-b (Figure B)
Figure-c (Figure C)
Figure-d (Figure D)
This text provides information about a lyophilized powder with an expiration date. The figure labeled as "Figure D" likely corresponds to the product or packaging. The format indicates that the product is in powdered form and should be used before the specified expiration date for optimal effectiveness.*
Figure-e (Figure E)
Figure-f (Figure F)
This text likely describes a figure (Figure F) showing a gray rod before and after a change or transformation.*
Figure-g (Figure G)
Figure-h (Figure H)
Figure-i (Figure I)
Figure-j (Figure J)
This text provides instructions for self-injection in two areas: the abdomen and upper thigh. The injections should be made 2 inches away from the navel in the abdomen, and in the upper thigh. Caregivers can also administer injections in these areas. The outer upper arm is also mentioned as a possible injection site. The figure labeled "J" likely provides a visual guide for proper injection locations.*
Figure-k (Figure K)
Figure-l (Figure L)
This is a set of brief instructions for a cap or lid that needs to be handled carefully. The text indicates not to pull the gray cap but instead to hold, twist, and pull off the cap in a specific manner. The instructions seem to correspond with a figure labeled as Figure L, with variations a, b, and c.*
Figure-m (Figure M)
Figure-n (Figure N)
This text describes an action involving two rods - an orange rod and a gray rod. The gray rod is being pushed down on the orange needle guard. This description may be relating to a mechanical or assembly process involving these components.*
Figure-o (Figure O)
This is not a readable text.*
Figure-p (Figure P)
Figure-q (Figure Q)
Figure-2 (Figure2 July22)
This text provides information about the proportion of subjects with a weekly average pain intensity rating scale (PP NRS) of less than 2%. It includes data from two studies, Olympia 1 and Olympia 2, comparing the treatment groups NEVLUVIO Q4W and Placebo. The number of subjects in each group is also mentioned.*
Turn-over (Turn Over)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
